News and Press Releases
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
10 March 2025 -- London, UK and New York, US -- OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2025
Vertex Announces UK MHRA Approval of ALYFTREK (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulatorfor the Treatment of Cystic Fibrosis
Deutivacaftor/tezacaftor/vanzacaftor approved for people with cystic fibrosis 6 years and older with at least one responsive mutation in the CFTR gene, including additional mutations not previously approved with other CFTR...
Category: Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025
Innovaderm Research Rebrands as Indero, a dual-focus CRO
7 March 2025 -- Quebec, Canada -- Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025
Medable Achieves Landmark CNIL Approval, Expanding Access for Digital Clinical Trials Across the European Union
4 March 2025 -- California, US -- Medable Inc., a leading provider of clinical development technology, announced that its eConsent and eCOA solutions have been approved for use in two...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025
Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections
Lead candidate in the ABX-01 programme to progress into first-in-human clinical studies Programme designed to treat Gram-negative bacterial lung infections in the most vulnerable patients. 4 March 2025 -- London,...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
4 March 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
Mural Health and ICON Announce Partnership to Enhance Participant and Site Experience in Clinical Trials
4 March 2025 -- Pennsylvania, US and Dublin, Ireland -- Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc, a global healthcare intelligence and clinical research...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 4, 2025
Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studies
Hydrocelin is potentially a first-in-class disease-modifying injectable treatment for osteoarthritis Pivotal clinical trial in osteoarthritis patients on track to start in 2025. 4 March 2025 -- Liege, Belgium -- Allegro...
Category: Biotechnology, Clinical Trials, Drug Delivery, Pharmaceutical
Posted: March 4, 2025
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
25 February 2025 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: February 25, 2025
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom
The Bloc Launches In.Pazienti Global Community at the 7th Patient Centricity & Collaboration World Congress
25 February 2025 -- London, UK -- Today, at the 7th Patient Centricity & Collaboration World Congress in London, The Bloc unveiled In.Pazienti, a global community that connects, supports, and...
Category: Clinical Trials, Drug Discovery, Other
Posted: February 25, 2025
ONWARD Medical Announces Publication of One-Year Study Showing Benefit of Sustained Access to ARC-EX Therapy
Study shows significant functional improvements after one year of ARC-EX Therapy Improvements were observed throughout one-year treatment period with no plateau Results demonstrate the importance of sustained access to ARC-EX...
Category: Biotechnology, Clinical Trials, Other
Posted: February 25, 2025
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Ingelheim, Germany – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931,...
Category: Biotechnology
Posted: February 24, 2025
Bioxodes secures new funds to reach early 2025 milestones and pursue Series B financing
Bioxodes raises €2.7 million from existing investors in Series A extension Interim data from BIRCH intracerebral hemorrhage (ICH) Phase 2a trial in Q1 2025 Recruitment of up to 16 additional...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 12, 2025
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 versus...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 10, 2025
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds
7 February 2025 -- Bagsværd, Denmark -- Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 7, 2025
